Safety of immune checkpoint inhibitors (nivolumab and pembrolizumab) in patients with solid cancers: A
Latest Information Update: 20 Jun 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Colon cancer; Head and neck cancer; Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
Most Recent Events
- 20 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology